Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$3.95
-0.3%
$3.79
$2.90
$11.16
$348.62M0.072.80 million shs1.93 million shs
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$3.95
+2.3%
$4.24
$3.31
$6.52
$1.37B1.236.23 million shs3.35 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$825.86
+0.6%
$768.01
$623.78
$935.63
$781.25B0.473.51 million shs2.21 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$53.02
-0.4%
$56.56
$45.05
$114.19
$236.47B0.6812.67 million shs8.46 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$34.42
+1.5%
$28.57
$18.92
$81.73
$3.87B0.644.90 million shs4.38 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
-0.25%+3.13%+0.77%-3.19%-41.22%
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
+2.33%+3.13%-1.00%-21.00%-39.60%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.60%+2.78%+11.23%+1.74%-8.54%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-0.40%-2.55%-9.80%-26.02%-54.17%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+1.47%+2.65%+29.25%0.00%-43.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$3.95
-0.3%
$3.79
$2.90
$11.16
$348.62M0.072.80 million shs1.93 million shs
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$3.95
+2.3%
$4.24
$3.31
$6.52
$1.37B1.236.23 million shs3.35 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$825.86
+0.6%
$768.01
$623.78
$935.63
$781.25B0.473.51 million shs2.21 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$53.02
-0.4%
$56.56
$45.05
$114.19
$236.47B0.6812.67 million shs8.46 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$34.42
+1.5%
$28.57
$18.92
$81.73
$3.87B0.644.90 million shs4.38 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
-0.25%+3.13%+0.77%-3.19%-41.22%
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
+2.33%+3.13%-1.00%-21.00%-39.60%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.60%+2.78%+11.23%+1.74%-8.54%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-0.40%-2.55%-9.80%-26.02%-54.17%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+1.47%+2.65%+29.25%0.00%-43.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
2.38
Hold$17.40340.51% Upside
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
2.33
Hold$5.8046.84% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.68
Moderate Buy$938.6113.65% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.50
Moderate Buy$76.0043.34% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2.81
Moderate Buy$85.62148.74% Upside

Current Analyst Ratings Breakdown

Latest LLY, NVO, GDRX, ALT, and VKTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/25/2025
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-)Sell (D+)
10/24/2025
Altimmune, Inc. stock logo
ALT
Altimmune
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/24/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
10/24/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/24/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$80.00 ➝ $75.00
10/23/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$98.00 ➝ $102.00
10/23/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$105.00
10/23/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
10/21/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHoldStrong Sell
10/20/2025
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$12.00
10/20/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$840.00 ➝ $930.00
(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$20K17,431.35N/AN/A$1.74 per share2.27
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$792.32M1.73$0.32 per share12.42$1.89 per share2.09
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B17.35$14.24 per share57.99$15.03 per share54.95
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$42.12B5.62$3.90 per share13.58$4.66 per share11.38
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$7.90 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$95.06M-$1.18N/AN/AN/A-438,730.03%-62.63%-55.29%11/11/2025 (Estimated)
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$16.39M$0.1039.5021.941.724.33%8.86%4.50%11/4/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$15.3053.9826.541.1925.91%92.72%16.89%10/30/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.6414.5711.382.4135.60%78.64%24.51%11/5/2025 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$109.96M-$2.12N/AN/AN/AN/A-28.23%-27.36%N/A

Latest LLY, NVO, GDRX, ALT, and VKTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2025Q3 2025
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.29N/AN/AN/A$0.00 millionN/A
11/5/2025Q3 2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.90N/AN/AN/A$11.98 billionN/A
11/4/2025Q3 2025
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$0.09N/AN/AN/A$195.17 millionN/A
10/30/2025Q3 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.42N/AN/AN/A$16.09 billionN/A
10/22/2025Q3 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.67-$0.81-$0.14-$0.81N/AN/A
8/12/2025Q2 2025
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.32-$0.27+$0.05-$0.27$0.00 million$0.01 million
8/7/2025Q2 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.59$6.31+$0.72$6.29$14.40 billion$15.56 billion
8/6/2025Q2 2025
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$0.10$0.09-$0.01$0.04$205.72 million$203.07 million
8/6/2025Q2 2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.93$0.97+$0.04$0.91$77.51 billion$11.69 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.73%N/A39.22%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.821.55%N/A22.53%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest LLY, NVO, GDRX, ALT, and VKTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/6/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.41192.4%8/18/20258/18/20258/26/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
0.09
20.44
20.44
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
0.75
4.21
4.21
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.86
1.28
1.00
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.52
0.78
0.56
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
25.86
25.86

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
63.77%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
4.40%
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
4.53%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5088.26 million84.37 millionOptionable
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
950347.45 million331.71 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
47,000946.46 million945.23 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
77,3494.47 billion4.46 billionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20112.44 million107.84 millionOptionable

Recent News About These Companies

What is Leerink Partnrs' Estimate for VKTX FY2029 Earnings?
Viking Therapeutics, Inc. (VKTX) Q3 2025 Earnings Call Transcript
Earnings Preview For Viking Therapeutics
Viking Therapeutics (VKTX) Receives a Buy from Oppenheimer
Trump jab sinks NVO, LLY, VKTX, AMGN, ALT

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Altimmune stock logo

Altimmune NASDAQ:ALT

$3.95 -0.01 (-0.25%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$3.98 +0.02 (+0.63%)
As of 10/24/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

GoodRx stock logo

GoodRx NASDAQ:GDRX

$3.95 +0.09 (+2.33%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$3.95 0.00 (0.00%)
As of 10/24/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$825.86 +4.82 (+0.59%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$826.28 +0.41 (+0.05%)
As of 10/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$53.02 -0.21 (-0.39%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$53.09 +0.07 (+0.13%)
As of 10/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$34.42 +0.50 (+1.47%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$34.48 +0.06 (+0.19%)
As of 10/24/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.